The factors determining positive detection rate of 68Ga PSMA PET/CT in patients with early biochemical recurrence prostate cancer
Received Date : 10 Jul 2019
Accepted Date : 16 Oct 2019
Available Online : 24 Oct 2019
Doi: 10.1016/j.jons.2019.10.001 - Article's Language: EN
J Oncol Sci 5 (2019) 100-104
This is an open access article under the CC BY-NC-ND license
Aim: To examine predictive markers for high detection rates of 68Ga PSMA-PET/CT in biochemical recurrence (BR) prostate cancer (PCa) patients with low PSA levels. Material and Method: This trial was planned as a retrospective single center study. Patients with BR prostat cancer were included. PSA levels of all patients were lower 2 mg/l. Results: Totally thirty-two men patients with BR PCa were included in this study. 18 (56.3%) patients underwent radical prostatectomy and 14 (43.7%) patients curative intense radiotherapy. The number of patients received adjuvant maximal androgen blokage (MAB) treatment was 15 (46.9%). Median PSA levels was calculated 1.03 mg/l 17 (53.1%) of patients had <1 mg/l PSA levels and 7 (21.8%) of patients <0.5 mg/l. The patients number was 16 in unfavorable intermediate risk group (50.0%), 12 (37.5%) in high group and 4 (12.5%) in very high group. The median PSA doubling time was 6.2 months. The number of patients received adjuvant MAB treatment was 15 and in 14 (93.3%) of patients were found positive lesion in 68Ga PSMA-PET/CT. The number of patients with at least one lesion detected on 68Ga PSMAPET/ CT was 19 (59.4%). In univariate analysis to detect the factors affecting 68Ga PSMA-PET/CT positivity, there was only the presence of adjuvant MAB treatment as statistically significant importance (p < 0.001) and in multivariate analysis, the presence of adjuvant MAB treatment was found to be as statistically significant factor in terms of affecting 68Ga PSMA-PET/CT positivity (p ¼ 0.003). The cut-off value was calculated as 1.12 mg/l in patients with no adjuvant MAB treatment (sensitivity 80% and specificity 83.3%). Conclusion: Clinicians may perform 68Ga PSMA PET/CT in low PSA levels to detect lesions in biochemical recurrent prostate cancer patients who had received MAB treatment and in patients with higher PSA levels who had no received MAB treatment.
  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA A Cancer J Clin. 2014;64:9e29. [Crossref]  [PubMed] 
  2. Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14: 15e25. [Crossref]  [PubMed]  [PMC] 
  3. Aus G, Abbou CC, Bolla M, et al. EAUguidelines on prostate cancer. Eur Urol. 2005;48:546e551. [Crossref]  [PubMed] 
  4. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14:e28ee37. 2045(12)70510-7. [Crossref] 
  5. Kosuri S, Akhtar NH, Smith M, et al. Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostatespecific membrane antigen radioimmunotherapy. Adv Urol. 2012;2012:921674. 921674. [Crossref]  [PubMed]  [PMC] 
  6. Rauscher I, Maurer T, Beer AJ, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016;57:1713e1719. jnumed.116.173492. [Crossref]  [PubMed] 
  7. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668e674. jnumed.115.154153. [Crossref]  [PubMed] 
  8. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197e209. [Crossref]  [PubMed]  [PMC] 
  9. Brito AET, Mourato FA, de Oliveira RPM, et al. Evaluation of whole-body tumor burden with 68Ga-PSMA PET/CT in the biochemical recurrence of prostate cancer. Ann Nucl Med. 2019;33:344e350. 01342-z. [Crossref]  [PubMed] 
  10. Yilmaz U, Komek H, Can C, et al. The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax. Ann Nucl Med. 2019. ([Epub ahead of print]). [Crossref]  [PubMed] 
  11. Hohberg M, Kobe C, T€ager P, et al. Combined early and late [68Ga]PSMA-HBEDFig CC PET scans improve lesion detectability in biochemical recurrence of prostate cancer with low PSA levels. Mol Imaging Biol. 2019;21:558e566. https:// [Crossref]  [PubMed] 
  12. Hope TA, Goodman JZ, Allen IE, et al. Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60:786e793. Epub 2018 Dec 7. [Crossref]  [PubMed]  [PMC] 
  13. Bashir U, Tree A, Mayer E, et al. Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2019;46:901e907. 10.1007/s00259-018-4249-z. [Crossref]  [PubMed]  [PMC]